Clobes Thomas A, Mee Marshall M, Jimenez Jenna M, Maldonado Jesus, Song Joshua R
Department of Health Sciences, California State University Channel Islands, Camarillo, CA, USA.
Department of Psychology, California State University Channel Islands, Camarillo, CA, USA.
Med Cannabis Cannabinoids. 2025 Feb 18;8(1):47-57. doi: 10.1159/000544125. eCollection 2025 Jan-Dec.
Cannabis as a therapeutic agent is accessible to a growing number of people, though research suggests that many medical cannabis (MC) users undertake their cannabinoid therapy independently, without collaborating with a cannabis clinician or informing their primary care provider (PCP). The effects of medical collaboration or disclosure to PCP on outcomes of cannabinoid therapy are unknown. Researchers anticipate that those who collaborate with a cannabis clinician or disclose their medical cannabis use to their PCP will find MC to be more effective, use less delta-9-tetrahydrocannabinol (THC) and more cannabidiol (CBD), and experience fewer side effects.
Through an online survey, medical cannabis users reported their cannabis usage patterns, health outcomes, PCP awareness, and collaboration with cannabis clinicians. These responses were analyzed using a variety of statistical tests to search for differences in reported efficacy, specific cannabinoid, and side effects between different levels of medical professional involvement ( = 988).
Patients who either worked with a cannabis clinician or reported their use of their PCP reported significantly higher efficacy ( < 0.001), and in the case of working specifically with a cannabis clinician, higher daily doses of cannabidiol were used ( < 0.001). CBD doses did not vary between those who had disclosed their MC use to their PCP and those who had not. There were no significant differences in THC doses or side effects identified between groups.
The results indicated that undertaking cannabinoid therapy with PCP awareness or guidance from a cannabis clinician is associated with better outcomes.
越来越多的人可以使用大麻作为治疗剂，不过研究表明，许多医用大麻（MC）使用者在没有与大麻临床医生合作或告知其初级保健提供者（PCP）的情况下，自行进行大麻素治疗。医用大麻治疗过程中与医生合作或向初级保健提供者披露相关情况对治疗结果的影响尚不清楚。研究人员预计，那些与大麻临床医生合作或向初级保健提供者披露其使用医用大麻情况的人会发现医用大麻更有效，使用的Δ-9-四氢大麻酚（THC）更少、大麻二酚（CBD）更多，且副作用更少。
通过在线调查，医用大麻使用者报告了他们的大麻使用模式、健康状况、初级保健提供者的知晓情况以及与大麻临床医生的合作情况。使用各种统计测试对这些回答进行分析，以寻找不同程度医疗专业人员参与（n = 988）之间在报告的疗效、特定大麻素和副作用方面的差异。
与大麻临床医生合作或向初级保健提供者报告其使用情况的患者报告的疗效显著更高（P < 0.001），并且在专门与大麻临床医生合作的情况下，使用的大麻二酚每日剂量更高（P < 0.001）。向初级保健提供者披露其使用医用大麻情况的患者与未披露的患者之间，大麻二酚剂量没有差异。各组之间在四氢大麻酚剂量或副作用方面没有显著差异。
结果表明，在初级保健提供者知晓或在大麻临床医生指导下进行大麻素治疗与更好的治疗结果相关。
